Welcome to our dedicated page for CME GROUP SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CME GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CME GROUP's regulatory disclosures and financial reporting.
CME Group Inc. Chief Transformation Officer Ken Vroman reported an open-market sale of Class A common stock. On March 12, 2026, he sold 5,160 shares at a weighted average price of $309.00 per share, with individual trade prices ranging from $308.969 to $309.11. Following this transaction, he directly holds 14,910 CME Group Class A common shares.
CME Group Inc. provides its proxy statement and invites shareholders to the 2026 annual meeting on May 14, 2026. The company highlights record 2025 financial results, including $6.5 billion in revenue, record average daily volume of 28.1 million contracts, and declared more than $4 billion in total dividends, including an aggregate variable dividend of $2.2 billion. The proxy lists voting items: election of 14 Equity directors, ratification of Ernst & Young LLP as auditor, an advisory vote on executive compensation, proposed amendments to eliminate certain Class B director election rights (ITEMS 4–7), and election of Class B directors under ITEM 8. The materials describe board composition, governance practices, risk oversight, compensation highlights, shareholder engagement activities, and other corporate governance disclosures.
Morgan Stanley Smith Barney LLC Executive Financial Services reported proposed sales under a Form 144 of several equity award lots, including 2,947 Performance Shares dated 03/15/2024 and multiple Restricted Stock lots dated 03/16/2024, 09/15/2024, and 09/15/2025 with counts of 498, 180, 475, 525, and 535 respectively.
CME Group Inc. director Elizabeth A. Cook reported an indirect open-market sale of 1,000 shares of Class A common stock held by a trust on March 6, 2026, at $320 per share. After this transaction, the trust’s indirect holdings totaled 17,771 CME Group shares.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting a proposed sale of 1,000 common shares tied to CME with an aggregate value listed as $320,000.00 and an execution date of 03/06/2026.
The filing also lists restricted stock lots of 748 shares with grant date 06/25/2024 and 252 shares with grant date 06/26/2023.
CME Group Inc: The Vanguard Group filed Amendment No. 9 to a Schedule 13G/A reporting 36,248,559 shares beneficially owned, representing 10.10% of common stock. The filing states shared voting power 3,697,661 and shared dispositive power 36,248,559. It notes an internal realignment effective 01/12/2026 that changed portfolio management and proxy voting roles within The Vanguard Group, Inc.
CME Group Inc. files its annual report outlining a broad derivatives, clearing, cash markets and data business built around global benchmark futures and options, cash U.S. Treasuries, FX and market data services. The company emphasizes deep liquidity, risk management and capital efficiency for a diverse institutional customer base.
In 2025, futures and options average daily volume reached 28.1 million contracts, with strong growth in interest rates, agricultural, energy and metals products and micro contracts. Cash markets via BrokerTec and EBS generated $283.7 million in clearing and transaction fees. CME estimates average daily margin savings of about $72 billion from portfolio offsets and cross‑margining.
CME highlights strategic initiatives in product expansion, global distribution, OTC alternatives, crypto, environmental products and a major multi‑year migration of core systems to Google Cloud. It is launching a new securities clearing subsidiary to support upcoming SEC U.S. Treasury and repo clearing mandates and continues to grow licensing and benchmark businesses such as CME Term SOFR. The report also details extensive regulatory oversight, key risk factors and human capital metrics, including roughly 3,875 employees worldwide and strong engagement scores.
CME Group Inc. director Bryan T. Durkin reported an open-market sale of Class A common stock. On February 23, 2026, he sold 4,200 shares at a weighted average price of $309.65 per share, within a price range of $309.25 to $310.07. After this transaction, he directly holds 43,007 shares of CME Group Class A common stock.
CME Group submitted a Form 144 reporting a proposed sale of common shares. The notice lists a broker, Morgan Stanley Smith Barney LLC, and an intended sale date of 02/23/2026. The filing itemizes equity awards: 218 performance stock units (03/15/2021), 3,285 performance stock units (03/15/2021) and 697 restricted shares (09/15/2019).
CME Group Inc. director Martin J. Gepsman reported an open-market sale of Class A common stock. He sold 300 shares at a price of $305.90 per share. After this sale, he directly owns 24,999 shares of CME Group Class A common stock.